Cyteir Therapeutics Gross Profit vs. Number Of Shares Shorted

CYTDelisted Stock  USD 2.76  0.01  0.36%   
Based on Cyteir Therapeutics' profitability indicators, Cyteir Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Cyteir Therapeutics' ability to earn profits and add value for shareholders.
For Cyteir Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyteir Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyteir Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyteir Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyteir Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Please note, there is a significant difference between Cyteir Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyteir Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyteir Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cyteir Therapeutics Number Of Shares Shorted vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cyteir Therapeutics's current stock value. Our valuation model uses many indicators to compare Cyteir Therapeutics value to that of its competitors to determine the firm's financial worth.
Cyteir Therapeutics is rated below average in gross profit category among its peers. It is rated below average in number of shares shorted category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Cyteir Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Cyteir Number Of Shares Shorted vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Cyteir Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
(16.59 M)
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Cyteir Therapeutics

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
319.73 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Cyteir Number Of Shares Shorted Comparison

Cyteir Therapeutics is currently under evaluation in number of shares shorted category among its peers.

Cyteir Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cyteir Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyteir Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cyteir Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cyteir Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company was incorporated in 2012 and is based in Lexington, Massachusetts. Cyteir Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.

Cyteir Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cyteir Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyteir Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyteir Therapeutics' important profitability drivers and their relationship over time.

Use Cyteir Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyteir Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyteir Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Cyteir Therapeutics Pair Trading

Cyteir Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Cyteir Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyteir Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyteir Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyteir Therapeutics to buy it.
The correlation of Cyteir Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyteir Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyteir Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyteir Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cyteir Therapeutics position

In addition to having Cyteir Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Growth Funds Thematic Idea Now

Small Growth Funds
Small Growth Funds Theme
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in Cyteir Stock

If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
CEOs Directory
Screen CEOs from public companies around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance